Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing ‘next-generation cell therapeutics’ - Inks strategic platform license agreement with Legend Biotech Corp, a firm focused in cell therapy. Under the terms of the agreement, Legend Biotech will get a non-exclusive worldwide license to use MaxCyte’s Flow Electroporation technology and ExPERT platform in connection with the research, clinical development and commercialisation of cell-based therapeutical products. Accordingly, MaxCyte will be allowed to receive annual licensing fees and milestones from Legend during clinical development.
Chief Executive Officer Maher Masoud says: ‘We are looking forward to supporting Legend Biotech’s non-viral engineered cell therapy program as they expand their portfolio with new delivery modalities. As a leading provider of cell-engineered platform technologies for drug developers, our global infrastructure allows us to provide Legend Biotech with technical, scientific, and regulatory support to advance its non-viral engineered therapeutic pipeline across all major regions.’
Current stock price: 370.50 pence
12-month change: up 18%
Copyright 2024 Alliance News Ltd. All Rights Reserved.